Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "'''contains verified protocol'''" to "'''contains dosing details in manuscript'''") |
||
| Line 32: | Line 32: | ||
===References=== | ===References=== | ||
| − | # '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains | + | # '''MyPathway:''' Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. [https://doi.org/10.1200/JCO.2017.75.3780 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/29320312 PubMed] NCT02091141 |
[[Category:EGFR regimens]] | [[Category:EGFR regimens]] | ||
Revision as of 12:52, 29 August 2022
1 regimens on this page
1 variants on this page
|
All lines of therapy
Erlotinib monotherapy
Regimen
| Study | Evidence |
|---|---|
| Hainsworth et al. 2018 (MyPathway) | Phase 2a, <20 pts in this arm |
Biomarker eligibility criteria
- Gene: EGFR
- Alteration: nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions
- Acceptable methods of measurement: molecular profiling performed on tissue obtained at the most recent tumor biopsy
- Biomarker exclusions: EGFR exon 20 mutations
Targeted therapy
- Erlotinib (Tarceva) 150 mg PO once per day
Continued indefinitely
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains dosing details in manuscript PubMed NCT02091141